Incyte (NASDAQ:INCY – Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60), Briefing.com reports. Incyte had a return on equity of 0.75% and a net margin of 2.52%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $0.77 EPS. Incyte’s quarterly revenue was up 9.3% on a year-over-year basis.
Incyte Stock Performance
NASDAQ INCY opened at $64.42 on Friday. Incyte has a 1 year low of $50.27 and a 1 year high of $70.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.89 and a quick ratio of 3.43. The stock has a market capitalization of $12.41 billion, a PE ratio of 19.52, a P/E/G ratio of 1.15 and a beta of 0.73. The company’s 50 day simple moving average is $61.74 and its two-hundred day simple moving average is $58.80.
Insiders Place Their Bets
In other news, EVP Vijay K. Iyengar sold 15,571 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total value of $1,089,970.00. Following the transaction, the executive vice president now owns 36,701 shares of the company’s stock, valued at approximately $2,569,070. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Thomas Tray sold 1,093 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $58.91, for a total transaction of $64,388.63. Following the transaction, the insider now owns 21,634 shares of the company’s stock, valued at approximately $1,274,458.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Vijay K. Iyengar sold 15,571 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the transaction, the executive vice president now directly owns 36,701 shares in the company, valued at approximately $2,569,070. The disclosure for this sale can be found here. Insiders have sold 45,282 shares of company stock worth $2,876,911 in the last three months. 17.50% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Read Our Latest Report on Incyte
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Read More
- Five stocks we like better than Incyte
- Using the MarketBeat Dividend Yield Calculator
- Investors Flock to Auto Retail Stock as It Hits New Highs
- The How and Why of Investing in Gold Stocks
- Take a Bite: This Snack Giant Is a Safe-Haven Stock Worth Buying
- What Are Trending Stocks? Trending Stocks Explained
- EA’s New Game Launch Boosts Stock: Is It Time to Buy?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.